Brian Posner Buys 2,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were purchased at an average cost of $18.21 per share, for a total transaction of $36,420.00. Following the purchase, the director directly owned 20,000 shares in the company, valued at approximately $364,200. This trade represents a 11.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded up $0.40 during midday trading on Thursday, reaching $18.56. 1,270,310 shares of the stock were exchanged, compared to its average volume of 1,988,207. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The firm has a 50-day simple moving average of $18.27 and a two-hundred day simple moving average of $18.31. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the firm posted ($1.05) earnings per share. As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Dyne Therapeutics by 63.5% in the 1st quarter. Bank of America Corp DE now owns 1,443,313 shares of the company’s stock valued at $26,167,000 after acquiring an additional 560,391 shares in the last quarter. California State Teachers Retirement System grew its position in shares of Dyne Therapeutics by 15.6% during the first quarter. California State Teachers Retirement System now owns 139,663 shares of the company’s stock worth $2,532,000 after buying an additional 18,863 shares in the last quarter. Royal Bank of Canada grew its position in shares of Dyne Therapeutics by 267.6% during the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock worth $1,236,000 after buying an additional 49,641 shares in the last quarter. Rock Springs Capital Management LP grew its position in shares of Dyne Therapeutics by 6.5% during the first quarter. Rock Springs Capital Management LP now owns 972,198 shares of the company’s stock worth $17,626,000 after buying an additional 59,243 shares in the last quarter. Finally, Quantinno Capital Management LP grew its position in shares of Dyne Therapeutics by 53.2% during the first quarter. Quantinno Capital Management LP now owns 19,297 shares of the company’s stock worth $350,000 after buying an additional 6,704 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on DYN shares. Morgan Stanley reduced their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Chardan Capital restated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright reduced their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.